Postępy Dermatologii i Alergologii

Full text

5/2026 vol. 43
Review paper

Physical urticaria: how to effectively control symptoms

Maria Zofia Lisiecka 1

  1. Individual Specialist Medical Practice, Warsaw, Poland

Adv Dermatol Allergol 2026; XLIII (5): 466-479

DOI: https://doi.org/10.5114/ada.2026.165953
Data publikacji online: 2026/10/22
Article file
PDiA Physical.pdf
  1. Nowicki RJ, Grubska-Suchanek E, Jahnz-Ró¿yk K, et al. Urticaria. interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society and the Polish Society of Allergology. Dermatol Rev 2020; 107: 1-14.
  2. Can P, Kocatürk E. Symptomatic dermographism versus chronic spontaneous urticaria; a detailed analysis of clinical features, treatment responses, and comorbidities. Asthma Allergy Immunol 2024; 22: 227-84.
  3. Raciborski F, K³ak A, Czarnecka-Operacz M, et al. Epidemiology of urticaria in Poland – nationally representative survey results. Adv Dermatol Allergol 2018; 35: 67-73.
  4. Bergmann KC, Altrichter S, Maurer M. Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism. J Eur Acad Dermatol Venereol 2019; 33: e413-5.
  5. Di Girolamo A, Miniello A, Casella R, et al. Successful treatment of refractory heat urticaria with omalizumab. Adv Dermatol Allergol 2024; 41: 429-31.
  6. Martina E, Diotallevi F, Bianchelli T, et al. Novel therapeutic approaches and targets for treatment of chronic urticaria: new insights and promising targets for a challenging disease. Curr Pharm Biotechnol 2021; 22: 32-45.
  7. Hershkovitz Y, Khanimov I, Rubin L, et al. Successful ligelizumab treatment of severe refractory solar urticaria. J Allergy Clin Immunol Pract 2023; 11: 2576-7.
  8. Özkaya E, Babuna Kobaner G, Yılmaz Z, Kutlay A. Doxepin in difficult-to-treat chronic urticaria: a retrospective, cross-sectional study from Turkey. Dermatol Ther 2019; 32: e12993.
  9. Gatica-Ortega ME, Sánchez-Albisua B, Arranz-Sánchez DM, et al. Erythema, localized edema and heat vs forearm perimeter increase. Time to revise the consensus recommendations on the vortex provocation test in vibratory urticaria-angioedema? Actas Dermosifiliogr 2024; 116: T357-64.
  10. Lesiak A, Bieñ N, Lipiñska K, et al. The effectiveness of omalizumab therapy in patients with chronic spontaneous urticaria: the experience of a single-centre study in Poland. Adv Dermatol Allergol 2024; 41: 301-5.
  11. Ariasi C, Perazzolli G, Rubelli L, et al. Successful omalizumab treatment in delayed pressure urticaria as confirmed by stimulation test. An Bras Dermatol 2025; 100: 399-400.
  12. Kayiran MA, Akdeniz N. Diagnosis and treatment of urticaria in primary care. North Clin Istanb 2019; 6: 93-9.
  13. Diaz VL, Gribbons KB, Yazdi-Nejad K, et al. Cold urticaria syndromes: diagnosis and management. J Allergy Clin Immunol Pract 2023; 11: 2275-85.
  14. Pezzolo E, Peroni A, Gisondi P, Girolomoni G. Heat urticaria: a revision of published cases with an update on classification and management. Br J Dermatol 2016; 175: 473-8.
  15. McSweeney SM, Kloczko E, Chadha M, et al. Systematic review of the clinical characteristics and natural history of solar urticaria. J Am Acad Dermatol 2023; 89: 138-40.
  16. Jawhar Z, Alshammari N, Al Radhwan N, Bluwi B. Acquired and familial cold-induced urticaria: a review. Int J Med Dev Ctries 2024; 8: 1742-6.
  17. Zhang L, Peng C, Li J. Shedding light on dermographism: a narrative review. Int J Dermatol 2024; 63: 999-1006.
  18. Alrafiaah AS, Netchiporouk E, Ben-Shoshan M. Cold-induced anaphylaxis triggered by drinking cold water. Allergol Immunopathol 2024; 52: 45-7.
  19. Anstey KM, Otani IM. Physical urticarias: diagnosis and testing. In: Allergic and Immunologic Diseases: A Practical Guide to the Evaluation, Diagnosis and Management of Allergic and Immunologic Diseases. Chang C (ed.). Elsevier, Philadelphia 2022; 389-399.
  20. Fonseca LC, Rodrigues C, Lemos AJ. Cholinergic urticaria: a case report. Cureus 2022; 14: e30869.
  21. Durda J, Wedi B, Martin V, Breuer K. Hyperresponsiveness to antihistamines in spontaneous urticaria and heat urticaria. Allergol Select 2017; 1: 222-6.
  22. Garbán PA, Rosado A, Macías Iglesias J, et al. Exhaustive diagnosis of heat urticaria in a regular clinical practice: report of 2 cases. J Investig Allergol Clin Immunol 2023; 34: 56-7.
  23. Harris BW, Crane JS, Schlessinger J. Solar urticaria. Treasure Island: StatPearls Publishing 2023.
  24. Chan S, Denman S, Savic S. Effective use of omalizumab for treatment of cold induced urticaria. Conference of the British Society for Allergy and Clinical Immunology 2016.
  25. Chu AWL, Rayner DG, Chu X, et al. Topical corticosteroids for hives and itch (urticaria): systematic review and bayesian meta-analysis of randomized trials. J Am Acad Dermatol 2024; 133: 437-44.
  26. Godse K, Godse G, Patil A. Skin writometer: a novel instrument for assessing provocation threshold in patients with symptomatic dermographism. IP Indian J Clin Exp Dermatol 2021; 7: 178-80.
  27. Pesqué D, Ciudad A, Andrades E, et al. Solar urticaria: an ambispective study in a long-term follow-up cohort with emphasis on therapeutic predictors and outcomes. Acta Derm Venereol 2024; 104: adv25576.
  28. Boyden SE, Desai A, Cruse G, et al. Vibratory urticaria associated with a missense variant in ADGRE2. N Engl J Med 2016; 374: 656-63.
  29. Kulthanan K, Rujitharanawong C, Munprom K, et al. Prevalence, clinical manifestations, treatment, and clinical course of chronic urticaria in elderly: a systematic review. J Asthma Allergy 2022; 15: 1455-90.
  30. Soliman YS, Lim HW, Kerr HA. Recalcitrant, delayed pressure urticaria treated with long-term intravenous immunoglobulin. JAAD Case Rep 2020; 6: 176-77.
  31. Sánchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J 2021; 14: 100533.
  32. Stepaniuk P, Vostretsova K, Kanani A. Review of cold-induced urticaria characteristics, diagnosis and management in a western Canadian allergy practice. Allergy Asthma Clin Immunol 2018; 14: 85.
  33. Mehta H, Janaani P, Vinay K, et al. Cold urticaria in tropics: a clinico-epidemiological study from North India. Indian J Dermatol Venereol Leprol 2023; 91: 369-73.
  34. Cakmak ME, Yegit OO, Öztop N. A case-control study comparing the general characteristics of patients with symptomatic dermographism and chronic spontaneous urticaria: is atopy a risk factor for symptomatic dermographism? Int Arch Allergy Immunol 2023; 185: 247-52.
  35. Xu JP, Zhang XB, Jiang QX, et al. Efficacy, safety, and serum cytokine modulation by olopatadine hydrochloride and desloratadine citrate disodium combination therapy in urticaria. Am J Transl Res 2024; 16: 2501-8.
  36. Parkin D, Ling TC, Ayer J, et al. “Omalizumab changed my life”: a patient perspective on solar urticaria. Clin Exp Dermatol 2024; 49: 935-6.
  37. Guarneri F, Guarneri C, Marini HR. Amitriptyline and bromazepam in the treatment of vibratory angioedema: which role for neuroinflammation? Dermatol Ther 2014; 27: 361-4.
  38. Smola A, Hawerkamp HC, Oláh P, et al. Omalizumab treated urticaria patients display T-cell and thrombocyte-associated gene regulation. Immun Inflamm Dis 2025; 13: e70132.
  39. Wu S, Ye X, Liu X, et al. Dermatologists’ knowledge, attitudes, and practices regarding omalizumab therapy for chronic urticaria. Arch Dermatol Res 2025; 317: 309.
  40. Tuncay G, Damadoglu E, Karakaya G, Kalyoncu AF. Comparison of the characteristics of patients with chronic urticaria receiving standard- or high-dose omalizumab. Eur Ann Allergy Clin Immunol 2026: 58: 69-76.
  41. Alix VC, Weiss SL, White KM. Delayed pressure urticaria associated with altitude chamber training responsive to cyclosporine and omalizumab. Mil Med 2024; 189: 2710-4.
  42. Cihanbeylerden M, Teixeira J, Kayıkçı H, et al. Assessing risk factors for relapse following omalizumab discontinuation in chronic urticaria. Allergy 2025; 80: 1495-7.
  43. Faenza M, Molle M, Mazzarella V, et al. Functional and aesthetic comparison between grafts and local flaps in non-melanoma skin cancer surgery of the face: a cohort study. JPRAS Open 2024; 42: 97-112.
  44. Hartmane I, Ivdra I, Mikaþâns I, Bondare-Ansberga V. Correlation of immunological and clinical changes in psoriasis patients treated with tumour necrosis factor-alpha (TNF-a) blocking biologic drugs: one-year dynamic observation. Proc Latv Acad Sci B Nat Exact Appl Sci 2021; 75: 357-63.
  45. Bogoyavlenskiy A, Alexyuk M, Alexyuk P, et al. Computer analysis of the inhibition of ACE2 by flavonoids and identification of their potential antiviral pharmacophore site. Molecules 2023; 28: 3766.
  46. Merkhatuly N, Iskanderov AN, Abeuova SB, Iskanderov AN. Synthesis of push-pull azulene-based compounds. Euras J Chem 2023; 2023: 36-41.
  47. Abisheva S, Rutskaya-Moroshan K, Nuranova G, et al. Antimalarial drugs at the intersection of SARS-CoV-2 and rheumatic diseases: what are the potential opportunities? Medic 2024; 60: 1171.
  48. Berezenko VS, Mykhailiuk KZ, Krechko YV, et al. Ornithine transcarbamylase deficiency is a little-known rare disease in pediatric hepatology (clinical case). Modern Pediatr Ukr 2022; 7: 111-6.
  49. Cimmino G, De Nisco M, Alonso C, et al. Novel synthesized seleno-glycoconjugates as cosmeceutical ingredients: antioxidant activity and in vitro skin permeation. Eur J Med Chem Rep 2024; 12: 100240.
  50. Picone C, Fusco R, Tonerini M, et al. Dose reduction strategies for pregnant women in emergency settings. J Clin Med 2023; 12: 1847.
  51. Adekenov SM, Gafurov NM, Turdybekov KM, et al. Transannular cyclization of the E,E-germacradienolide hanphyllin. Chem Nat Comp 1992; 28: 444-51.
  52. Adekenov SM, Gafurov NM, Turmukhambetov AZ. Chemical modification of estafiatin. Chem Nat Comp 1991; 27: 571-5.
  53. Cimmino G, De Nisco M, Piccolella S, et al. Innovative cosmeceutical ingredients: harnessing selenosugar-linked hydroxycinnamic acids for antioxidant and wound-healing properties. Antioxidants 2024; 13: 744.
  54. Manghisi VM, Fiorentino M, Boccaccio A, et al. A body tracking-based low-cost solution for monitoring workers’ hygiene best practices during pandemics. Sens 2020; 20: 1-17.
  55. Alpern ML, Campbell RL, Rank MA, et al. A case of vibratory anaphylaxis. Ann Allergy Asthma Immunol 2016; 116: 588-9.
  56. Casanova-Esquembre A, Lorca-Spröhnle J, Peñuelas-Leal R, Pérez-Ferriols A. Solar urticaria and omalizumab: a retrospective case-control study and follow-up. Actas Dermosifiliogr 2024; 115: 931-2.
  57. Medici A, Luongo G, Pedatella S, et al. Tackling losartan contamination: the promise of peroxymonosulfate/Fe(II) advanced oxidation processes. Molecules 2024; 29: 2237.
  58. González C, De Nisco M, Lemos R, et al. New glycoconjugates containing selenium and polyphenols: stereoselective synthesis by pummerer-like rearrangement. Eur J Org Chem 2025; 28: e202500291.
  59. Boontaveeyuwat E, Willis F, Fassihi H, Sarkany RPE. Successful serial plasmapheresis for solar urticaria, a case report and literature review. J Dermatolog Treat 2024; 35: 2350229.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications